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ABSTRACT
Background
West Nile virus (WNV) is endemic in the US, varying seasonally and by geographic region.
WNV can be transmitted by blood transfusion, and mandatory screening of blood for WNV was
recently introduced throughout the US. Guidelines for selecting cost-effective strategies for
screening blood for WNV do not exist.
Methods and Findings
We conducted a cost-effectiveness analysis for screening blood for WNV using a computer-
based mathematical model, and using data from prospective studies, retrospective studies, and
published literature. For three geographic areas with varying WNV-transmission intensity and
length of transmission season, the model was used to estimate lifetime costs, quality-adjusted
life expectancy, and incremental cost-effectiveness ratios associated with alternative screening
strategies in a target population of blood-transfusion recipients. We compared the status quo
(baseline screening using a donor questionnaire) to several strategies which differed by nucleic
acid testing of either pooled or individual samples, universal versus targeted screening of
donations designated for immunocompromised patients, and seasonal versus year-long
screening. In low-transmission areas with short WNV seasons, screening by questionnaire alone
was the most cost-effective strategy. In areas with high levels of WNV transmission, seasonal
screening of individual samples and restricting screening to blood donations designated for
immunocompromised recipients was the most cost-effective strategy. Seasonal screening of
the entire recipient pool added minimal clinical benefit, with incremental cost-effectiveness
ratios exceeding US$1.7 million per quality-adjusted life-year gained. Year-round screening
offered no additional benefit compared to seasonal screening in any of the transmission
settings.
Conclusions
In areas with high levels of WNV transmission, seasonal screening of individual samples and
restricting screening to blood donations designated for immunocompromised recipients is cost
saving. In areas with low levels of infection, a status-quo strategy using a standard
questionnaire is cost-effective.
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The ﬁrst US-based case of West Nile virus (WNV) disease
was reported in New York in 1999 [1]; since then, the virus has
spread across the country, leading to 16,637 detected cases of
WNV-associated illness and 647 WNV-associated deaths from
1999 to 2004, inclusive (http://www.cdc.gov/).
WNV is a neuropathic ﬂavivirus, transmitted from birds to
humans via the mosquito vector. Naturally acquired infection
is most often asymptomatic; about 20% of those infected
develop a ﬂu-like illness characterized by fever, while a
smaller proportion (less than 1%) develop neuroinvasive
disease (NI). WNV-associated NI can result in death or in
serious sequelae; these poor outcomes occur most commonly
in elderly and immunocompromised patients [2].
The Centers for Disease Control and Prevention (CDC)
recently reported on the ﬁrst 23 patients infected through
blood transfusion, six of whom died [3]. Although they are a
very small minority of the WNV cases reported, transfusion-
acquired infections are potentially avoidable, and public
health authorities moved quickly to try to safeguard the blood
supply from the virus. The Food and Drug Administration
(FDA) accelerated the approval of two investigational nucleic
acid-based blood-safety tests, and screening of donations was
initiated by July 2003 [4]. WNV was subsequently detected in
818 blood donations [3], leading public health ofﬁcials to
conclude that the screening program had prevented at least
some WNV transmission. Nonetheless, at least six cases of
transfusion-associated WNV have been reported since the
initiation of the testing, raising concern that current testing
strategies may be inadequate.
The choice of optimal screening strategy will likely depend
on the prevalence of WNV infection among donors, the
duration of the epidemic season, the dilution of the pooled
samples, and the underlying health status of blood-trans-
fusion recipients. Although screening of blood by nucleic acid
test (NAT) is currently mandated by the FDA, actual
implementation of screening strategies is largely at the
discretion of the individual states and the blood-collection
agencies. For example, the FDA speciﬁes that testing must be
performed in all states from May until the end of October,
but allows year-long testing if states deem it necessary [4].
Similarly, NAT can be performed on individual blood
donations or on pooled samples. Compared to individual
sample testing, the pooling of samples lowers screening costs
at the expense of diminished assay sensitivity [5]. Further-
more, current policy mandates screening blood for all
transfusion recipients. A subset of transfusion recipients
may have an impaired immune response owing to malig-
nancy, HIV, or to the use of immunosuppressive drugs.
Targeted screening of blood designated for immunocompro-
mised patients, who are most at risk of developing severe
consequences following WNV infection, may be an alter-
native to universal screening. This approach has been used to
prevent transfusion-associated cytomegalovirus infection in
immunocompromised patients [6].
To identify the most medically effective and cost-effective
screening strategies under a range of different circumstances,
we conducted a cost-effectiveness analysis of alternative
strategies for WNV blood screening and considered the effects
of variable assay characteristics, transfusion outcomes, and
pricing that may affect current and future policy decisions.
Methods
Analytic Overview
We developed a state-transition model to simulate the
natural history of WNV infection transmitted from blood
donors to transfusion recipients. The model was used to
estimate lifetime costs, life expectancy, and quality-adjusted
life expectancy for different blood-screening strategies in a
target population of people receiving blood transfusions.
Since the cost-effectiveness of screening depends on the
prevalence of infectious cases among blood donors, the
analyses were performed for three different populations of
donors residing in states in which the incidence of WNV
varies in intensity and duration of the natural transmission
season. Parameters describing the natural history of trans-
fusion-associated WNV were derived from the literature. The
implications of alternative parameter values were evaluated
in sensitivity analyses. We chose the 95% conﬁdence interval
of estimated probabilities to establish clinical parameter
ranges, and we consulted experts in the ﬁeld to establish price
and assay ranges.
We adopted a societal perspective and followed the
reference-case recommendations of the Panel on Cost-
Effectiveness in Health and Medicine [8]. Future costs and
QALYs saved were discounted at an annual rate of 3%.
Alternative screening strategies were compared using the
ICER. We assessed the internal consistency and face validity
of our model by predicting the number of transfusion cases
for each state for 2002 and comparing these outputs with the
number of cases reported to state health departments for that
year (R. J. Powell, K. Signs, R. Timperi, K. A. Winpisinger,
personal communications). We conducted extensive sensitiv-
ity analyses to evaluate the stability of our conclusions over a
wide range of parameter estimates and assumptions.
Strategies
We considered four main WNV-screening strategies to be
added to baseline screening of blood donors for general
infectious diseases. Baseline screening involves the distribu-
tion of a donor questionnaire that elicits information about
any recent history of fever and is designed to ensure that the
blood of individuals with active infections is excluded from
the blood supply. Blood centers design their own question-
naires about general health and well being based on donor-
eligibility rules established by the FDA (http://
americanredcrossblood.org/). An abbreviated physical exami-
nation includes checking for abnormalities in blood pressure,
pulse, and temperature (http://www.aabb.org/). The four
WNV-screening strategies to be superimposed on the ques-
tionnaire include: (1) nucleic acid testing of minipools of 16
samples (MP16-NAT) followed by testing the samples in a
reactive pool by individual nucleic acid test (ID-NAT); (2)
nucleic acid testing of minipools of six samples (MP6-NAT)
followed by individual testing of the samples in a reactive
pool by ID-NAT; (3) nucleic acid testing of individual samples
by ID-NAT; and (4) individual nucleic acid testing on blood
donations designated for immunocompromised recipients
only. We also evaluated the implications of ‘‘seasonal
targeting,’’ meaning that supplemental strategies would be
brought into operation only during the ‘‘high incidence’’
WNV season from May through to the end of October in
contrast to year-round screening.
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We constructed a Markov model for each of the three
WNV-transmission scenarios described in Table 1. Markov
models depict the natural history of disease as an evolving
sequence of health states, deﬁned to capture important
clinical outcomes, each of which is associated with speciﬁc
costs. The time horizon of the analysis incorporates a
transfusion recipient’s lifetime and is divided into equal
weekly increments during which transitions between health
states occur. The following ﬁve mutually exclusive health
states included in this model describe the various WNV
infection and disease statuses of people after they have
received a blood transfusion: (1) no WNV infection or
asymptomatic infection; (2) WNV infection leading to febrile
illness only; (3) WNV infection leading to NI with no long-
term sequelae; (4) WNV infection leading to NI associated
with long-term sequelae leading to either institutionalized or
home care; or (5) death (Figure 1). Individuals entering the
model are assumed to be uninfected at the time of trans-
fusion and are assigned gender, age, age-speciﬁc post-trans-
fusion life expectancy, and immune status based on the
distribution of these characteristics in previously studied
transfused populations [9].
Transition probabilities derived from a review of the
literature were used to move transfusion recipients through
different health states over time until all the members of the
transfused cohort had died. For example, upon transfusion,
each individual faced a risk of transfusion-acquired WNV
infection. The risk of infection varied depending on the
sensitivity and speciﬁcity of the speciﬁc screening strategies
being analyzed. We assumed that a WNV-positive blood
donation always resulted in infection but that the risk of
disease in those who were infected was higher in elderly and
immunocompromised patients. Once infected, individuals
progressed through a week-long incubation period after
which they could either remain asymptomatic or make the
transition to a health state characterized by febrile illness
only or by NI, with or without long-term sequelae or death.
Patients who moved into the febrile-illness-only state either
recovered or died within 1 wk from causes unrelated to WNV
infection, while those in the NI state faced a weekly
probability of recovery, death from WNV, or death from
unrelated causes.
Natural History of Transfusion-Acquired WNV
We estimated the weekly probability that a unit of
transfused blood would be infected with WNV in each of
the three transmission scenarios using a method developed by
Biggerstaff et al. [10,11]. Following this approach, we used
data on the dates of onset of detected neuroinvasive cases,
estimated distributions of WNV incubation, symptomatic and
viremic periods, and the ratio of detected to undetected
infections to estimate the number of potential blood donors
with WN viremia at each time point over a 1-y period. Dates
of onset of naturally acquired WNV-associated NI for each of
the three scenarios, which were based on corresponding
WNV-associated NI case data, were obtained from the CDC
Arbonet surveillance Team for 2002. Based on data from
previous serological studies, we estimated that, for every
reported case of WNV-associated NI, 140 cases of WNV
infection had occurred that were either asymptomatic or had
presented with fever only [12]. We then used the dates of
symptom onset of the detected cases as ‘‘anchor times’’ from
which we generated, for each non-NI case, a date of infection,
onset of viremia, onset of symptoms, resolution of symptoms,
and resolution of viremia. By dividing the number of viremic
individuals by the state population, we determined the
probability of WNV infection among the general population
for a given week for each scenario.
Figure 2 illustrates the potential viremic donor times.
Without detection by NAT, asymptomatic individuals could
Table 1. WNV Disease Characteristics in General Population
Giving Rise to Risk in Hypothetical Transfusion Cohorts
Infection Pattern
a Number of Naturally
Acquired WNV Cases
per Million, 2002
Duration of Human
Epidemic (d)
Low infection/
short duration
3.39 August 2–October 5 (65)
High infection/
long duration
67.20 June 24–December 14 (174)
High infection/
short duration
88.10 August 4–October 15 (73)
aNumbers for low-infection/short-duration pattern based on data from Massachusetts; numbers for high-infection/
long-duration pattern based on data from Mississippi; numbers for high-infection/short-duration pattern based on
data from Nebraska (Source: CDC Arbonet).
DOI: 10.1371/journal.pmed.0030021.t001
Figure 1. Post-Transfusion Health States
Five post-transfusion health states were identified. Following transfusion,
individuals entered the uninfected or asymptomatic infection state,
febrile-illness state, or NI state and progressed to other health states in
the direction of the arrows. Individuals were followed until death.
DOI: 10.1371/journal.pmed.0030021.g001
Figure 2. Potential Donor Time for an Infected Individual
A potential blood donor who develops WNV symptoms is viremic and
eligible to donate for a longer period of time as the latent period
decreases and the incubation period increases. A potential blood donor
who recovers from symptoms in a short amount of time may be eligible
to donate before viremia ends.
DOI: 10.1371/journal.pmed.0030021.g002
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Variable Baseline
Value
Values for
Sensitivity Analysis
Sources
Parameters used to generate probability of infectious blood donor
Latent period (d) 1–2 [10,11,13,35]
Incubation period (d) 2–6 [10,11,35,36]
Febrile period (d) 3–6 [12]
Viremic period (d) 1–11 [10–13]
Probability symptomatic due to naturally acquired WNV infection 0.21 [10–12]
Probability donor symptomatic due to other infections 0.11 [12]
Clinical characteristics of blood recipients
Probability male blood-transfusion recipient 0.62 [14]
Probability immunocompromised 0.27 [14]
Age distribution of blood-transfusion recipients [14]
Age , 41 y (%) 15
Age 41–65 y (%) 25
Age . 65 y (%) 60
Probability febrile for blood-transfusion recipients
a [13]
Age , 41 y, non-immunocompromised 0.83
Age 41–65 y, non-immunocompromised 0.65
Age . 65 y, non-immunocompromised 0.62
Immunocompromised 0.38
Probability of seeking care for febrile symptoms 0.20
Probability of developing NI for blood-transfusion recipients
a [13]
Age , 41 y, non-immunocompromised 0.0 0.0, 0.46
Age 41–65 y, non-immunocompromised 0.06 0.01, 0.17
Age .65 y, non-immunocompromised 0.08 0.002, 0.36
Immunocompromised 0.63 0.24, 0.92
Length of hospital stay for NI http://www.ahrq.gov/, [16]
Age   65 y (wk) 1
Age . 65 y (wk) 2
Probability of death from NI http://www.ahrq.gov/, [1,15,16]
Age   65 y 0.02
Age . 65 y 0.16
Probability requiring institutional care at discharge 0.30 (D. Nash and A. K. Labowitz,
personal communication), [19]
Probability requiring institutional care past 8 wk 0.20 [15]
Probability requiring home care at discharge 0.40 (D. Nash and A. K. Labowitz,
personal communication), [19]
Probability requiring home care beyond 6 mo 0.13 (D. Nash and A. K. Labowitz,
personal communication)
Screening-test characteristics: MP16-NAT
Sensitivity (%) 9.0 96.0 http://www.fda.gov/
Specificity (%) 99.9
Screening-test characteristics: MP6-NAT
Sensitivity (%) 37.2 98.0 http://www.innovations-report.de/html/berichte/
medizin_gesundheit/bericht-24048.html
Specificity (%) 99.9
Screening-test characteristics: ID-NAT
Sensitivity (%) 44.8 99.0 [22]
Specificity (%) 99.8
Screening costs, US$ in 2003
b
Laboratory technician, hourly rate
c 19 (R. Timperi, personal communication)
Discarded sample 90 (R. Timperi, personal communication), [26]
Donor notification, retrieval of sample 500 (R. Timperi, personal communication), [26]
Test kit, per sample
d (R. Timperi, personal communication)
ID-NAT 3 1.50, 6.00
MP6-NAT 0.50 0.25, 1.00
MP16-NAT 0.19 0.09, 0.38
Treatment costs, US$ in 2003
b
Febrile case 200
NI case 38,417 [27]
Institutional care (1 y) 135,078 [28]
Home care (1 y) 37,602 http://www.bls.gov/
Quality weights: non-infected, asymptomatically, febrile states Male, female [23]
Age , 45 y 1.00, 1.00
Age 45–54 y 0.76, 0.76
Age 55–64 y 0.74, 0.74
Age 65–74 y 0.73, 0.71
Age 75–84 y 0.68, 0.67
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Alternative Blood-Screening Strategiesdonate on any day. Durations of the incubation, viremic, and
symptomatic periods were derived from the literature; the
ranges of these values are given in Table 2. Once the time line
of infection was generated for each case, we counted the
number of potential donors who were viremic on each day
during the course of a year, and generated a curve represent-
ing the prevalence of viremic blood donors over the time
course of the simulation. We repeated the simulation 1,000
times to obtain Monte Carlo averages of the prevalence of
viremic donors, and these averages were then used to estimate
the probability that a blood-transfusion recipient would be
transfused with WNV-infected blood. By designing our model
to output the weekly probability of a viremic donation, we
were able to evaluate the impact of implementing supple-
mental assay screening for selected weeks within the year.
Clinical Data
Clinical parameters [13–20] used in the model are shown in
Table 2. Since there are few data on death from NI due to
WNV, we used national hospital data on death from NI due to
multiple causes collected by the Healthcare Cost and
Utilization Project (http://www.ahrq.gov/hcupnet/). We uti-
lized unpublished follow-up data on 36 hospitalized patients
with WNV to estimate long-term recovery from WNV-
associated NI (D. Nash and A. K. Labowitz, personal
communication). Distributions of age, sex, and immune
status for transfusion recipients were based on transfusion
look-back studies [14]. Since there are no population-based
studies that reported the probability of developing febrile
illness or NI after acquiring transfusion-associated WNV
infection, we relied on data from an experimental study of
deliberate WNV inoculation of humans with cancer [13]. Age
and sex-speciﬁc background mortality for the blood recipi-
ents was based on a transfusion-cohort study [21].
Screening Tests
Table 2 summarizes baseline estimates of test sensitivity
and speciﬁcity for ID-NAT [22]. ID-NAT sensitivity was
derived from a study [22] which compared methods of virus
detection in macaques experimentally inoculated with WNV.
The sensitivities of MP6-NAT and MP16-NAT relative to ID-
NAT were estimated from data on the proportion of ID-
NAT–positive samples that were identiﬁed by minipool tests;
FDA meeting transcripts (http://www.fda.gov/ohrms/dockets/
ac/03/transcripts/4014T1.htm) and a publicly available Web
site (http://www.innovations-report.de/html/berichte/
medizin_gesundheit/bericht-24048.html) provided these da-
ta. In the absence of deﬁnitive data, we assumed that
speciﬁcity of these tests was high.
Health-Related Quality of Life
We used a quality-of-life well-being index to assign quality
weights to uninfected and asymptomatically infected individ-
uals based on their age and sex [23]. Quality weights for the
NI state were based on a study of herpes simplex infection of
the central nervous system [24]. The quality weights for
neurological sequelae states requiring institutionalized care
and home care were based on a study of neurological sequelae
resulting from Haemophilus inﬂuenzae vaccination [25].
Costs
The cost estimates [26–28] used in the base case are shown
in Table 2. Direct costs for screening blood donors using
WNV assays included screening kit and reagents, laboratory
technician fees, and the costs of a discarded false positive,
donor notiﬁcation, and retrieval of a test-positive sample.
Since WNV assays have not yet been priced, we estimated
their cost from studies of similar assays for other viruses.
Other screening costs were obtained from state laboratories
(R. Timperi, personal communication) and could be corro-
borated with data from a screening study [26] for transfusion-
acquired malaria in Canada.
Direct medical costs for individuals with NI and neuro-
logical sequelae from WNV were derived from published
studies on other arboviral infections that lead to similar
clinical outcomes. These studies included detailed estimates
of resource utilization, including hospitalization, outpatient
visits, and laboratory tests. Data from the US Bureau of Labor
Statistics were used to assign a cost for the time required by
an individual to care for a homebound patient on a full-time
basis. To account for inﬂation, all costs were converted to
2003 US dollars by use of the Medical Care Component of the
Consumer Price Index (http://www.bls.gov/).
Results
Face Validity of the Model
For the year 2002, the model predicts plausible numbers of
transfusion-acquired WNV-associated NI cases. Assuming
Table 2. Continued
Variable Baseline
Value
Values for
Sensitivity Analysis
Sources
Quality weights: non-infected, asymptomatically, febrile states Male, female
Age . 84 y 0.61, 0.67
NI 0.19 [24]
Sequelae, institutionalized
e [25]
Sequelae, home care
e [25]
Estimates are reported as weekly probabilities unless otherwise noted.
aData from Southam and Moore [13] were stratified age , 30 y, age 30–60 y, and age . 60 y. Transfusion-survival analysis data [9,14,21] were stratified age , 41 y, age 41–65 y, and age . 65 y. Applied low, middle, and high age-category data
from Southam and Moore [13] to respective age categories determined by transfusion-survival analysis literature.
bThe medical care component of the consumer price index from Bureau of Labor Statistics (http://www.bls.gov/) was used to update values to 2003 US$.
cProcessing time for 182 samples is 5.5 h by ID-NAT; 2,912 samples can be processed by MP16-NAT in 5.5 h (http://www.fda.gov/). Based on this, we calculated that 1,092 samples could be processed by MP6-NAT in 5.5 h.
dEstimated to be similar to other NATs; commercial cost not yet determined.
eQuality weights associated with sequelae from NI were estimated by weighting the quality weights associated with the non-infected, asymptomatic, febrile state by values reported in prior studies of neurological sequelae.
DOI: 10.1371/journal.pmed.0030021.t002
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within the 95% tolerance intervals constructed by the
observed numbers of transfusion-acquired WNV-associated
NI cases by the relevant state health departments (Table 3).
Projected Clinical and Economic Outcomes
The clinical outcomes of the different screening strategies
in three different regions of varying transmission intensity
are presented in Table 4. In the absence of speciﬁc screening
for WNV, we projected, per 2 million transfusions, a total of
277 cases of WNV infection plus 50 cases of NI for the high-
infection/short-duration epidemic scenario, and 205 cases of
WNV infection plus 46 cases of NI for the high-infection/
long-duration epidemic scenario. For the low-infection/short-
duration epidemic scenario, we projected eight cases of WNV
infection and one case of NI per 2 million transfusions.
Screening year-round did not prevent a greater number of
cases than did seasonal screening from May to the end of
October, even in areas with a long transmission season. The
introduction of screening by ID-NAT had no impact in the
low-intensity setting on the expected case numbers, but
reduced the expected number of infections and cases of NI in
the two higher-intensity settings. Screening with the MP6-
NAT and MP16-NAT also reduced the number of infections
and cases of NI, but was less effective than screening with ID-
NAT for the higher-transmission-intensity settings.
While the strategy of restricting screening to blood
designated for the immunocompromised population alone
prevented fewer infections than screening the entire pop-
ulation of blood donors with ID-NAT, there was little impact
on the number of cases of NI.
In the low-infection/short-duration scenario, the baseline
strategy of screening through questionnaire alone was the
least-costly and most cost-effective alternative; supplemental
screening strategies increased the total cost signiﬁcantly, but
did not reduce the number of cases or increase quality-
adjusted life expectancy in this setting (Table 5). In contrast,
several of the screening strategies in the higher-intensity
scenarios were less expensive and more cost-effective than
the questionnaire alone, since the incremental costs of
implementing these strategies were outweighed by the
averted direct medical costs. In the high-intensity/short-
duration setting, seasonal ID-NAT screening of blood
designated for transfusion of immunocompromised patients
was the most cost-effective of these strategies. Although
seasonal screening of the entire donor pool with ID-NAT was
nominally more effective, this was associated with an
incremental quality-adjusted life expectancy beneﬁt of less
than 1 min. Comparable results were obtained for the high-
intensity/long-duration scenario. In this setting again, season-
al screening with ID-NAT of blood designated for transfusion
of immunocompromised patients dominated the other
strategies, providing 3.6 min more of quality-adjusted life
expectancy than the questionnaire alone and at less cost.
Screening the entire donor pool with ID-NAT was slightly
more effective at the cost of US$1.7 million/QALY gained.
Sensitivity Analyses
Within areas of low infection /short duration of WNV, the
questionnaire alone remained the least-costly strategy across a
wide range of sensitivity analyses. When we assumed that assay
sensitivity was as high as other nucleic acid tests, seasonally
screening the entire donor pool by MP16-NAT was also on the
efﬁciency curve; however, the ICER was US$1.2 million/QALY
gained. Similarly, when we assumed an estimate from the high
end of the plausible range for the probability of severe disease,
ID-NAT added less than 1 min to the average quality-adjusted
life expectancy at a cost of US$1 million/QALY. Further
details are shown in Tables S1–S6.
For areas with high infection/short duration, the rank
order of strategies was sensitive to variations in test sensitivity
and the risk of developing severe disease. When we assumed
the high assay sensitivity, seasonally screening the entire
donor pool by MP6-NAT was the least-costly strategy;
seasonally screening the entire donor pool by ID-NAT was
also on the efﬁciency curve but exceeded US$7 million/
QALY. When we assumed a high risk of severe disease,
unrestricted seasonal screening by ID-NAT was the only non-
dominated strategy. We also evaluated the effect of shortened
seasonal screening from mid-July to mid-October versus full
seasonal screening from May to the end of October for this
transmission area. Shortened seasonal screening offered the
same clinical beneﬁt at lower cost than full seasonal screen-
ing; targeted screening of blood designated for transfusion of
immunocompromised patients was the least-costly strategy.
The ICER for universal screening by ID-NAT versus targeted
screening of blood designated for transfusion of immuno-
compromised patients remained too high for universal
screening to be a cost-effective strategy, even with shortened
seasonal screening.
Table 3. Observed and Predicted Number of Transfusion-Acquired WNV-Associated NI Cases in 2002 with Status-Quo Screening
(Questionnaire)
State Number of Transfusions
a Observed Number of WNV
Transfusion-Acquired NI Cases
in 2002
b (95% Tolerance Intervals)
Predicted Number of WNV
Transfusion-Acquired NI
Cases in 2002
Ohio 196,473 1 (0.03, 5.57) 4
Oklahoma 60,081 2 (0.03, 5.57) 0
Massachusetts 116,620 0 (0.00, 3.69) 0
Michigan 172,920 4 (1.09, 10.24) 3
aNumber of transfusions¼total number of transfusions in the US per annum (http://www.givelife2.org/) multiplied by proportion of US population residing in that state (http://www.census.org/). Tolerance intervals based on assumption that
events are Poisson-distributed; for 0 observed events, one-sided 97.5% tolerance interval presented.
bObserved numbers from personal communications with: K. A. Winpisinger, Ohio Department of Public Health; R. J. Powell, Oklahoma Department of Public Health; R. Timperi, Massachusetts Department of Public Health; and K. Signs,
Michigan Department of Public Health.
DOI: 10.1371/journal.pmed.0030021.t003
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were sensitive to both improved assay sensitivity and changes
in assumptions about the risk of developing severe disease.
When we assumed high assay sensitivity, seasonal screening by
MP6-NAT was the only non-dominated strategy. When we
assumed an estimate from the low end of the plausible range
for risk of severe disease, the questionnaire strategy was least
costly, although seasonal screening by ID-NAT of blood
designated for transfusion of immunocompromised patients
offered additional clinical beneﬁt for an ICER of US$56,000/
QALY gained.
Discussion
The recent emergence of WNV in the US has led to a
perceived need to safeguard the blood supply from viremic
blood donations. Strategies for screening blood for emerging
viral infections such as WNV are often put into place without
systematic evaluation of their costs, beneﬁts, and cost-
effectiveness. In this study, we conducted a cost-effectiveness
analysis of alternative strategies for blood screening and
considered the efﬁcacy of these strategies in areas with
varying epidemic intensity, exploring the effect of variable
assay characteristics, transfusion outcomes, and pricing that
may affect current and future policy decisions.
Our analyses demonstrated that in areas with high
infection rates, in the order of those seen in Mississippi and
Nebraska in 2002, seasonal screening of blood designated for
immunocompromised recipients prolongs quality-adjusted
life expectancy compared with implementing a baseline
questionnaire alone. Although other strategies, such as
screening pooled samples designated for all donors, provided
some beneﬁt compared to a questionnaire alone, they were
more costly and either less effective or only marginally more
effective than restricted seasonal screening. In areas with low
infection and seasonal transmission, none of the NAT
strategies offered additional clinical beneﬁt given current
test-sensitivity estimates, although they were associated with
substantial costs. These results suggest that the general
screening of blood for WNV may not be as attractive a
public health strategy as it ﬁrst appeared to be, and that more
restricted screening strategies may be preferable to currently
mandated policies.
The ﬁnding that blood-screening strategies for WNV may
be outside the usually accepted cost-effectiveness thresholds
is consistent with previous cost-effectiveness analyses for
blood screening for infectious agents [21,29–32]. A recent
analysis of NAT screening for hepatitis B and C and HIV
compared to serological testing alone showed that the ICER
exceeded US$1.5 million/QALY gained, well beyond the
US$50,000–100,000 threshold commonly used as an indicator
of willingness to pay for a health-care intervention [21].
Table 4. Predicted Clinical Outcomes Associated with Supplemental NAT Blood Screening Relative to Status-Quo Screening
(Questionnaire)
Scenario NI Cases Febrile Cases Asymptomatic Infections Total Infections
Transmission with high infection/short duration
a
Status quo: questionnaire only 1.00 1.0 1.0 1.0
MP16-NAT, YR 0.90 0.91 0.91 0.91
MP6-NAT, YR 0.80 0.76 0.71 0.75
ID-NAT, YR 0.52 0.55 0.50 0.53
MP16-NAT, seasonal 0.90 0.91 0.91 0.91
MP6-NAT, seasonal 0.80 0.76 0.71 0.75
ID-NAT, seasonal 0.52 0.55 0.50 0.53
ID-NAT, Im only, YR 0.58 0.99 0.94 0.90
ID-NAT, Im only, seasonal 0.58 0.99 0.94 0.90
Transmission with high infection/long duration
a
Status quo: questionnaire only 1.0 1.0 1.0 1.0
MP16-NAT, YR 0.91 0.95 0.98 0.95
MP6-NAT, YR 0.80 0.80 0.89 0.83
ID-NAT, YR 0.59 0.57 0.56 0.57
MP16-NAT, seasonal 0.91 0.95 0.98 0.95
MP6-NAT, seasonal 0.80 0.80 0.89 0.84
ID-NAT, seasonal 0.59 0.57 0.56 0.58
ID-NAT, Im only, YR 0.67 0.95 0.90 0.87
ID-NAT, Im only, seasonal 0.67 0.95 0.90 0.87
Transmission with low infection/short duration
a
Status quo: questionnaire only 1.0 1.0 1.0 1.0
MP16-NAT, YR 1.0 0.80 0.5 0.75
MP6-NAT, YR 1.0 0.80 0.5 0.75
ID-NAT, YR 1.0 0.80 0.5 0.75
MP16-NAT, seasonal 1.0 0.80 0.5 0.75
MP6-NAT, seasonal 1.0 0.80 0.5 0.75
ID-NAT, seasonal 1.0 0.80 0.5 0.75
ID-NAT, Im only, YR 1.0 1.0 0.5 0.88
ID-NAT, Im only, seasonal 1.0 1.0 0.5 0.88
aNumbers for low-infection/short-duration pattern based on data from Massachusetts; numbers for high-infection/long-duration pattern based on data from Mississippi; numbers for high-infection/short-duration pattern based on data from
Nebraska (Source: CDC Arbonet).
Im only, screening of blood designated for immunocompromised patients only; YR, year-round screening; seasonal, screening from May to October, inclusive, only.
DOI: 10.1371/journal.pmed.0030021.t004
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reasons why cost-effectiveness estimates of blood-screening
tests are so unattractive; risks are relatively low, transfusion
recipients often have a reduced quality-adjusted life expect-
ancy, and costs are incurred for all donations, few of which
are infectious. Despite this, blood-screening tests are often
implemented for reasons that are not captured in a cost-
effectiveness analysis. There is a perception that blood
recipients cannot be held responsible for avoiding risk, and
therefore the system must protect them at any cost.
Individuals are willing to pay more to avoid a catastrophic
outcome, even when the risk is low compared to other
outcomes. Furthermore, policy makers are more likely to
apply an intervention to a small and deﬁned group such as
blood recipients rather than to a less-visible group [32].
Nonetheless, in an era of major cuts in public health
expenditure and increasingly limited resources available for
health care, it is worthwhile reconsidering the economic
implications of this priority; resources spent preventing the
rare case of transfusion-associated WNV might be better
utilized in a host of other interventions against infectious
disease, including those focused on reducing WNV trans-
mission through mosquito vectors. If such an approach were
successful, it might obviate the need for screening blood for
the virus in many areas.
Our analysis has a number of limitations as the ecology of
WNV in the US, and the clinical course and sequelae of
transfusion-acquired WNV infection, have not been clearly
deﬁned. Transmission intensities have varied over the years
within some geographic regions since the emergence of WNV.
Choosing the most cost-effective approach to screening
within a speciﬁc area will depend on the ability to predict
transmission intensity for the current season. Recently, a risk
equation based on mosquito abundance, infectivity, vector
competence, and host feeding behavior was developed to
predict short-term future human WNV infections in an area
[33]. The utility of this index to predict human infections is
under investigation. Methods to validate, and improve upon,
current prediction tools for WNV infection would enhance
our ability to select the most cost-effective screening
Table 5. Predicted QALYs, Costs, Clinical Outcomes, and ICERs Associated with NAT Blood Screening for WNV in a Cohort of 2,000,000
Scenario Total
Cost
(US$)
Cost
Incremental
to Next
Least-Costly,
Non-Dominated
Strategy (US$)
Total QALYs QALYs
Incremental
to Next
Least-Costly,
Non-Dominated
Strategy
Number
of NI
Cases
Number of
Febrile
Cases
Total
number of
infections
$/QALY $/Case
Averted
Transmission with high infection/short duration
a
ID-NAT, Im, seasonal 7,012,157 — 13,852,115.81 — 29 135 249 Cost saving Cost saving
ID-NAT, Im, YR 9,327,509 2,315,352 13,852,115.81 0.0 29 135 249 Dominated Dominated
MP6-NAT, seasonal 9,412,150 2,399,993 13,852,104.19  11.62 40 104 207 Dominated Dominated
MP16-NAT, seasonal 10,102,317 3,090,160 13,852,099.15  16.66 45 124 251 Dominated Dominated
Status quo: questionnaire only 10,743,984 3,731,827 13,852,092.39  23.42 50 137 277 Dominated Dominated
MP6-NAT, YR 10,793,006 3,780,849 13,852,104.19  11.62 40 104 207 Dominated Dominated
MP16-NAT, YR 11,145,084 4,132,927 13,852,099.15  16.66 45 124 251 Dominated Dominated
ID-NAT, seasonal 11,932,649 4,920,492 13,852,118.28 2.47 26 75 146 1,991,500 1,640,200
ID-NAT, YR 18,800,943 6,868,294 13,852,118.28 0.0 26 75 146 Dominated Dominated
Transmission with high infection/long duration
a
ID-NAT, Im, seasonal 7,156,235 — 13,852,116.43 — 31 92 179 Cost saving Cost saving
MP6-NAT, seasonal 8,357,291 1,201,056 13,852,110.77  5.66 37 80 172 Dominated Dominated
Status quo: questionnaire only 8,761,003 1,604,768 13,852,102.81  13.62 46 97 205 Dominated Dominated
MP16-NAT, seasonal 8,876,196 1,719,961 13,852,106.94  9.49 42 92 195 Dominated Dominated
ID-NAT, Im, YR 9,464,551 2,308,316 13,852,116.43 0.00 31 92 179 Dominated Dominated
MP6-NAT, YR 9,754,888 2,598,653 13,852,110.77  5.66 37 78 170 Dominated Dominated
MP16-NAT, YR 9,914,991 2,758,756 13,852,106.94  9.49 42 92 195 Dominated Dominated
ID-NAT, seasonal 12,055,271 4,899,036 13,852,119.32 2.89 27 57 119 1,693,800 3,266,000
ID-NAT, YR 18,961,134 6,905,863 13,852,119.32 0.0 27 55 117 Dominated Dominated
Transmission with low infection/short duration
a
Status quo: questionnaire only 131,008 — 13,852,140.13 — 1 5 8
MP16-NAT, seasonal 1,082,050 951,042 13,852,140.13 0.0 1 4 7 Dominated Dominated
ID-NAT, Im, seasonal 1,255,220 1,124,212 13,852,140.13 0.0 1 5 7 Dominated Dominated
MP6-NAT, seasonal 1,475,753 1,344,745 13,852,140.13 0.0 1 4 7 Dominated Dominated
MP16-NAT, YR 2,107,154 1,976,146 13,852,140.13 0.0 1 4 7 Dominated Dominated
MP6-NAT, YR 2,846,230 2,715,222 13,852,140.13 0.0 1 4 7 Dominated Dominated
ID-NAT, Im, YR 3,841,307 3,710,299 13,852,140.13 0.0 1 5 7 Dominated Dominated
ID-NAT, seasonal 7,004,908 6,873,900 13,852,140.13 0.0 1 4 6 Dominated Dominated
ID-NAT, YR 13,872,808 13,741,800 13,852,140.13 0.0 1 4 6 Dominated Dominated
Cost saving refers to the first two scenarios in the table described as ‘‘high infection/short duration’’ and ‘‘high infection/long duration,’’ where a strategy is available which is more effective and less costly than the status quo of using the
questionnaire only. Dominated refers to strategies that are more costly and less effective than other options; extended (weak) dominance refers to strategies having higher ICERs than more effective options.
aNumbers for low-infection/short-duration pattern based on data from Massachusetts; numbers for high-infection/long-duration pattern based on data from Mississippi; numbers for high-infection/short-duration pattern based on data from
Nebraska. (Source: CDC Arbonet.)
Im, screening of blood designated for immunocompromised patients only; YR, year-round screening; seasonal, screening from May to October, inclusive, only. All strategies relying on the incremental addition of nucleic acid testing assume
that the questionnaire is also being administered.
DOI: 10.1371/journal.pmed.0030021.t005
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monitor the mosquito population parameters that determine
virus transmission to humans would allow us to shift policy in
response to important temporal changes in transmission
patterns.
Lacking other data, we estimated the risk of developing NI
after an infected transfusion from a single study in which
patients with cancer were deliberately inoculated with WNV
[13]. These data may overestimate the true risk of disease,
since the patients studied may have been more susceptible to
severe disease than healthier blood recipients. Such a bias
would exaggerate the beneﬁts of screening in our analyses.
Otherwise, if the potentially higher dose of virus from a
transfusion-associated infection results in an even higher risk
of developing NI than we estimated, the beneﬁts of screening
are underestimated in our analyses [10,11]. In addition, in the
absence of large-cohort data, we assumed that data from
small studies on the long-term clinical consequences of WNV-
associated NI patients represent the expected sequelae of
infection.
Among the least well-deﬁned parameters used in this
analysis were those reﬂecting the performance of the newly
introduced nucleic acid–screening tests. These were FDA-
approved prior to establishing their sensitivity and speciﬁcity,
and these characteristics have yet to be published. Given the
imprecision of these estimates together with our expectation
that the assay will improve with further product develop-
ment, we repeated our analyses assuming that NAT for WNV
was highly sensitive and speciﬁc. However, this analysis
assumed that an improved test bore no additional cost. While
various measures to enhance detection of low levels of
viremia have been proposed, these would add further steps to
screening rather than replace existing approaches, possibly
adding substantially to expense. New methods that achieve
small boosts in sensitivity (such as IgM antibody testing as an
adjunct method to detect positive samples that have escaped
NAT detection) are unlikely to be cost-effective under the
assumptions made in this analysis. Custer et al. [34]
demonstrated that while continuous ID-NAT screening would
overburden blood-testing laboratories, ID-NAT screening
during select times of the transmission season is needed
currently, since minipool assays fail to detect 23% of the
viremic samples detected by ID-NAT.
In conclusion, we found that NAT screening of blood
donations for WNV improved clinical outcomes only in those
areas where the incidence of WNV is high, and that limiting
screening to high-intensity transmission seasons and to blood
donations designated for immunocompromised patients
reduced costs without decreasing quality-adjusted life expect-
ancy in most scenarios. We recommend that states adopt
screening policies based on the intensity and duration of
their WNV epidemics. Regional data, in conjunction with the
results of this analysis and consideration of societal risk
attitudes and preferences, may collectively point to a
relaxation of the current federally mandated NAT screening
of all donations in low-intensity areas. When high rates of
natural infection indicate that NAT screening is appropriate,
we recommend use of ID-NAT rather than minipool screen-
ing. States should consider the restricted screening of blood
designated for immunocompromised patients alone. Finally,
we suggest that blood-screening policies be carefully scruti-
nized for cost-effectiveness and that their relative contribu-
tion to safeguarding public health be considered in the
making of policy decisions.
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Table S6. Predicted QALYs, Costs, Clinical Outcomes, and ICERs
Box 1. Glossary.
Quality-Adjusted Life-Year A quality-adjusted life-year (QALY) takes
into account both quantity and the quality of life generated by health-
care interventions. It is the arithmetic product of life expectancy and a
measure of the quality of the remaining life-years. A QALY places a
weight on time in different health states. One year of perfect health is
worth 1; however, 1 y of less-than-perfect health life expectancy is worth
less than 1. Death is considered to be equivalent to 0 (http://www.
evidence-based-medicine.co.uk/ebmfiles/WhatisaQALY.pdf).
ICER The incremental cost-effectiveness ratio (ICER) is defined as the
additional cost of a specific strategy divided by its clinical benefit
compared with the next least-expensive strategy.
Cost Saving An intervention which costs less and is more effective than
its comparator is cost saving.
Dominated Strategies may cost more but be less effective (strongly
dominated), or cost more and be less cost-effective (weakly dominated),
than an alternative strategy.
Cost-Effective While there is no accepted standard for what constitutes
good value, the range from US$50,000 to US$100,000 per QALY has
often been used as a rough benchmark for the United States. Evidence
from some quarters suggests that this is too low. The most common
source supporting the US$50,000 threshold seems to be Medicare’s
decision in the 1970s to cover dialysis in patients with chronic renal
failure at a cost-effectiveness ratio within this range. Relatively recent
guidelines from the Commission on Macroeconomics and Health
suggest that interventions with cost-effectiveness ratios that are less
than the gross domestic product per capita are considered very cost-
effective, and that those with ratios that are less than three times the
gross domestic product per capita are considered cost-effective [7]. The
per-capita gross domestic product for the United States in 2004 was
US$40,100 (http://www.cia.gov/cia/publications/factbook/geos/us.html).
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Alternative Blood-Screening StrategiesPatient Summary
Background. West Nile virus (WNV) was first isolated from a sick woman
in the West Nile region of Uganda in 1937. The virus has subsequently
been found to be widespread in Africa and Eurasia, and sporadic
outbreaks have been reported throughout these regions. WNV was first
detected in the US in 1999, in a sick woman in New York. The disease has
since spread to most states in the continental US, making thousands of
people ill and causing several hundred deaths. Wild birds are the
principal host of WNV, and the virus is transmitted to humans mainly by
mosquitoes that bite both birds and humans. Most of the people who
get infected by a mosquito bite do not get sick at all, but about 20%
develop a flu-like illness. In a small number of cases—especially among
the elderly and people with a weakened immune system—the infection
spreads to the nervous system and can cause death or long-term
disability. Like other blood-borne diseases, WNV can be transferred by
blood transfusion with contaminated blood. Such cases have occurred in
the US and have killed few people.
Why Was this Study Done? WNV can be detected in blood samples by
recently developed and approved tests. These tests detect most, but not
all, cases of contamination with the virus. This means the WNV deaths
resulting from transfusion of contaminated blood are potentially
avoidable by screening donated blood. As a consequence, the US Food
and Drug Administration (FDA) has mandated screening of donated
blood samples. However, the FDA has not prescribed specific screening
strategies, and the decision on how to best screen blood samples has
been left to the individual states and the blood-collection agencies. The
researchers who carried out this study wanted to determine which
screening strategies would be cost-effective—that is, which strategies
would prevent infections through contaminated blood for a reasonable
price. In an ideal world, cost would not matter when it comes to
protecting human life and health, but in reality there is limited money
available for public health measures. Studies such as this one are
therefore essential to help politicians decide how to spend the money.
What Did the Researchers Do and Find? They calculated the costs of
screening and the number of prevented infections through blood
transfusion for a number of different scenarios. They found that in states
with low WNV infection rates, the risk of an infected person donating
blood was so low that screening was unlikely to prevent cases of serious
illness from WNV, despite substantial costs. In states where WNV is
common, screening throughout the year is likely to prevent cases of
serious illness, but at a substantial cost. In states where WNV is common,
screening blood only from May to the end of October (the months when
mosquitoes are around and people get infected from them), however,
was as effective at identifying contaminated blood samples as screening
throughout the year. One way to reduce costs substantially was to create
a separate blood pool that is reserved for transfusions to people with a
weakened immune system and to screen only those samples. Because
those are the people most at risk for severe WNV illness, this strategy
would still prevent most of those cases.
What Do These Findings Mean? It is not clear whether the current
policy to screen all blood samples in all states makes sense from a health
economy point of view. Restricting screening to states where WNV is
common and to samples designated for people at higher risk for severe
WNV illness would reduce costs significantly without putting the
recipients of blood transfusions at a substantially higher risk of serious
illness caused by WNV.
Where Can I Get More Information Online? The following Web sites
provide information on WNV.
Pages from the US Centers for Disease Control and Prevention:
http://www.cdc.gov/ncidod/dvbid/westnile/
Pages from the US National Biological Information Infrastructure:
http://westnilevirus.nbii.gov/
MedlinePlus pages:
http://www.nlm.nih.gov/medlineplus/westnilevirus.html
US Food and Drug Administration pages:
http://www.fda.gov/oc/opacom/hottopics/westnile.html
US Geological Survey pages:
http://westnilemaps.usgs.gov/
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